Common medications that increase the risk for developing community-acquired pneumonia

Area of Science:

• Pulmonology
• Pharmacology
• Infectious Diseases

Background:

• Community-acquired pneumonia (CAP) presents a significant global health challenge, marked by substantial morbidity, mortality, and economic burden.
• Emerging evidence suggests a link between certain medications and the incidence and severity of CAP.
• Patients with chronic obstructive lung disease (COPD) are particularly vulnerable to respiratory infections.

Purpose of the Study:

• To critically evaluate the association between inhaled corticosteroid (ICS) use in COPD patients and the risk of developing CAP.
• To review existing data on the relationship between gastric-acid suppressants (histamine-2 receptor antagonists and proton pump inhibitors) and the increased incidence of CAP.

Main Methods:

• Systematic literature review of observational studies and clinical trials.
• Analysis of data linking medication use (ICS, H2RAs, PPIs) to CAP diagnosis and outcomes.
• Exploration of potential pathogenetic mechanisms.

Main Results:

• Multiple studies indicate a correlation between inhaled corticosteroid use and an elevated risk of CAP.
• Evidence demonstrates that gastric-acid suppressants are associated with a higher incidence of CAP.
• Specific drug classes, including ICS and proton pump inhibitors, warrant further investigation regarding CAP risk.

Conclusions:

• The use of inhaled corticosteroids and certain gastric-acid suppressants may contribute to an increased risk of CAP in susceptible populations.
• Understanding these associations is crucial for optimizing treatment strategies and mitigating patient risk.
• Further research is needed to elucidate the precise mechanisms and clinical implications for healthcare systems.